Regeneron Pharmaceuticals Inc.

In News

Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas - Business Wire

Business Wire - May 18, 2026

Regeneron Shares Tumble After Fianlimab Study Failure - WSJ

WSJ - May 18, 2026

Regeneron immunotherapy combo comes up short in melanoma trial - BioPharma Dive

BioPharma Dive - May 18, 2026

Regeneron drops after skin cancer treatment fails late-stage trial - Reuters

Reuters - May 18, 2026

Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B - BioSpace

BioSpace - May 18, 2026

Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates - Pharmaceutical Technology

Pharmaceutical Technology - May 19, 2026

Regeneron wins FDA approval for first gene therapy for genetic hearing loss - Reuters

Reuters - Apr 23, 2026

Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda - Yahoo Finance

Yahoo Finance - May 18, 2026

Regeneron Sinks After Late-Stage Melanoma Trial Failure - Bloomberg.com

Bloomberg.com - May 18, 2026

Regeneron: Time To Forget Fianlimab (Rating Upgrade) (NASDAQ:REGN) - Seeking Alpha

Seeking Alpha - May 18, 2026

North Dakota State Investment Board Acquires Shares of 3,579 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

MarketBeat - May 19, 2026

Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy - Moomoo

Moomoo - May 19, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment